Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
NCT01545648 · Hope Rugo, MD · PHASE2 · terminated · last registry update 2020-01-02 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low Accrual” | – | Registry record, Hope Rugo, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-01-18Also stopped (withdrawn): Borstkanker Onderzoek Groep, Denosumab 120 mg + Denosumab 60 mg (NCT03532087)
- 2019-11-22Results posted on the registry: M.D. Anderson Cancer Center, Denosumab (NCT01952054)
- 2019-11-22Also stopped (terminated): M.D. Anderson Cancer Center, Denosumab (NCT01952054)
- 2019-09-09Results posted on the registry: Amgen, Denosumab (NCT01419717)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision